<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04299438</url>
  </required_header>
  <id_info>
    <org_study_id>834760</org_study_id>
    <nct_id>NCT04299438</nct_id>
  </id_info>
  <brief_title>Propranolol Rescue of Prolonged Labor</brief_title>
  <acronym>PROPEL</acronym>
  <official_title>Propranolol Rescue of Prolonged Labor (PROPEL): A Randomized, Double-blind, Placebo-controlled Multicenter Investigation of Propranolol's Effect on Cesarean Delivery Rate Among Women With Prolonged Labor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lisa Levine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blind placebo controlled randomized trial comparing cesarean delivery rates in women
      given IV propranolol versus placebo for treatment of prolonged labor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double-blind placebo controlled randomized trial comparing cesarean delivery rates in 326
      women given IV propranolol (2 mg with one possible repeat dose greater than 2 hours later)
      versus IV placebo for treatment of prolonged labor.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 14, 2020</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mode of Delivery</measure>
    <time_frame>From enrollment into the trial until delivery.</time_frame>
    <description>Percentage of women that have a cesarean delivery compared to a vaginal delivery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of Labor</measure>
    <time_frame>hours from start of labor or induction of labor to time of delivery</time_frame>
    <description>Time in hours from start of labor or induction of labor to delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postpartum hemorrhage</measure>
    <time_frame>from time of delivery through hospital discharge</time_frame>
    <description>Amount of blood loss measured in mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chorioamnionitis</measure>
    <time_frame>from start of labor through delivery</time_frame>
    <description>Counts of cases of chorioamnionitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal morbidity</measure>
    <time_frame>from delivery through 4 weeks postpartum</time_frame>
    <description>Counts of cases of 1 or more of the following: blood transfusion, endometritis, wound infection, venous thromboembolism, hysterectomy, ICU admission, readmission, death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal morbidity</measure>
    <time_frame>from delivery through hospital discharge</time_frame>
    <description>Counts of cases of 1 or more of the following: Intensive care nursery admission &gt;48, blood transfusion, hypoxic-ischemic encephalopathy, intraventricular hemorrhage grade 3 or 4, neonatal head cooling, severe respiratory distress syndrome, necrotizing enterocolitis, sepsis, death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">326</enrollment>
  <condition>Pregnancy, Prolonged</condition>
  <arm_group>
    <arm_group_label>Propranolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV Propranolol - 2mg; one possible repeat dose ≥2 hours later</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline placebo- 2 mL; one possible repeat dose ≥2 hours later</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol Hydrochloride</intervention_name>
    <description>2mg/mL vials</description>
    <arm_group_label>Propranolol</arm_group_label>
    <other_name>Inderal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>0.9% saline in vials matching the vials of the active drug</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        English-speaking

        &gt;= 36 weeks gestation

        Singleton pregnancy

        Vertex presentation

        No contraindication to a vaginal delivery

        Meets at least one study criteria for prolonged labor:

          1. cervical dilation &lt;6 cm after ≥12 hours with ruptured membranes and receiving oxytocin
             OR

          2. cervical dilation &gt;=6 cm and &lt;1 cm dilation change over ≥2 hours with ruptured
             membranes and receiving oxytocin

        Exclusion Criteria:

        Severe preeclampsia: as patients will be receiving magnesium and possibly labetalol for
        hypertension control

        Receiving other beta blocker

        Maternal heart rate &lt; 70 beats per minute, systolic blood pressure &lt;90 mmHg, or diastolic
        blood pressure &lt;50 mmHg on two sets of vital signs in the 1 hour prior to study drug
        administration: given that bradycardia and hypotension are possible side effects of
        propranolol

        Moderate or severe asthma: as this is a contraindication to beta blocker use

        Diabetes requiring insulin in labor: given the potential risk of neonatal hypoglycemia in
        the neonate

        Any cardiac condition for which β blockade is contraindicated (cardiogenic shock, sinus
        bradycardia, and greater than first degree heart block)

        Known hypersensitivity to propranolol

        Intrauterine fetal demise since different labor protocols are used in these women

        Major fetal congenital anomaly since rate of cesarean may be inherently different in these
        women, unrelated to labor
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Levine, MD, MSCE</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Director of Clinical Trial Oversight, WHCRC</last_name>
    <phone>203-662-3324</phone>
    <email>tracey.thomas@pennmedicine.upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lisa Levine, MD</last_name>
    <email>lisa.levine@pennmedicine.upenn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Levine, MD</last_name>
      <email>lisa.levine@pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Lisa Levine, MD, MSCE</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer McCoy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pennsylvania Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer McCoy, MD</last_name>
      <email>jennifer.mccoy@pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Lisa Levine, MD, MSCE</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer McCoy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 25, 2020</study_first_submitted>
  <study_first_submitted_qc>March 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2020</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Lisa Levine</investigator_full_name>
    <investigator_title>Assistant Professor of Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <keyword>Propranolol</keyword>
  <keyword>Cesarean</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregnancy, Prolonged</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

